C-SCADE8
A cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk
- Stage
- klaar
- Medicine
- BI 10773 (empagliflozine)
- Population
- Diabetes Mellitus
- Phase
- fase III
- First Patient In
- 1 January 2012
- Last Patient In
- 30 March 2018
- Last Patient Last Visit
- -
Study Director
